Trials / Completed
CompletedNCT04768855
A Study of LY3540378 in Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3540378 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3540378 in healthy participants following single and multiple doses (Parts A and B) and multiple doses in Japanese (Part C) and Chinese (Part D) healthy participants. Blood tests will be performed to check how much LY3540378 gets into the bloodstream and how long it takes the body to eliminate it. This is a 4-part study and may last up to 70, 113, 113 and 113 days for each participant in Parts A, B, C, and D respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3540378 | Administered IV or SC. |
| DRUG | Placebo | Administered IV or SC. |
| DRUG | LY3540378 | Administered SC. |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2022-05-30
- Completion
- 2022-05-30
- First posted
- 2021-02-24
- Last updated
- 2022-06-21
Locations
2 sites across 2 countries: United States, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04768855. Inclusion in this directory is not an endorsement.